Squarepoint Ops LLC Trims Stake in Medpace Holdings, Inc. $MEDP

Key Points

• Squarepoint Ops LLC cut its Medpace stake by 68.4% in the second quarter, selling 39,705 shares and retaining 18,370 shares worth approximately $9.7 million. Institutional investors overall own 77.98% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 in EPS versus the $3.98 consensus and $707.33 million in revenue, up 17.2% year over year. The company guided for fiscal 2026 EPS of $17.25–$17.95.
• Analysts maintain a generally cautious view, with three Buy ratings and nine Holds, producing an average “Hold” rating and a $595.20 price target. Meanwhile, insiders sold 134,471 shares worth approximately $82.2 million over the past 90 days.

Squarepoint Ops LLC lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 68.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,370 shares of the company's stock after selling 39,705 shares during the quarter. Squarepoint Ops LLC owned about 0.07% of Medpace worth $9,729,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in MEDP. NewEdge Advisors LLC increased its stake in Medpace by 22.1% in the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock worth $319,000 after acquiring an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock valued at $24,929,000 after acquiring an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Medpace during the second quarter worth about $296,000. Finally, M&T Bank Corp increased its position in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company's stock worth $295,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

MEDP stock opened at $583.16 on Friday. The company has a market capitalization of $16.28 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.62 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The company's 50 day moving average price is $578.40 and its two-hundred day moving average price is $504.09.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm's revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MEDP. Robert W. Baird raised their target price on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and upped their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $595.20.

Insider Buying and Selling at Medpace

In other news, Director Robert O. Kraft sold 3,858 shares of the business's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the sale, the director owned 955 shares of the company's stock, valued at approximately $590,008.55. The trade was a 80.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kevin M. Brady sold 3,400 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the sale, the chief financial officer owned 12,830 shares of the company's stock, valued at $8,021,829.20. This represents a 20.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 134,471 shares of company stock valued at $82,151,311. Corporate insiders own 20.50% of the company's stock.

About Medpace

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.